Document is current
Any future updates will be listed below
-
Authors
Chen, Hongrui
Hua, Chen
Chang, Shih-Jen
Qiu, Yajing
Lin, Xiaoxi
Sun, Bin
-
Funding
Funding for this research was provided by:
Fundamental research program funding of Ninth People's Hospital affiliated to Shanghai Jiao Tong university School of Medicine (JYZZ241)
Top Priority Research Center of Shanghai—Plastic Surgery Research Center, Shanghai (2023ZZ02023)
Treatment and mechanism of PI3K/mTOR dual-target inhibitor (WX390) on PIK3CA-related overgrowth spectrum (JYHX2022004)
Fundamental Research Funds for the Central Universities (YG2023ZD13)
- License Information
-
More Information
Article History
Received: 23 April 2025
Accepted: 28 August 2025
First Online: 1 October 2025
Declarations
:
: The study was approved by the Ethics Board of Shanghai Ninth Hospital, Shanghai Jiaotong University of Medicine (SH9H-2022-T215-1). Written informed consent forms were signed by patients or patients’ parents whose facial adipose sample were collected in this study. Title of the approved project: Treatment and mechanism of Pl3K/mTOR dual-target inhibitor (WX390) on PlK3CA-related overgrowth spectrum (PROS). Date of approval: 06, October, 2022. All animal procedures were performed following protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the Shanghai Jiao Tong University School of Medicine (SH9H-2022-A916-1). Title of the approved project: Etiological Research on Limb Developmental Defects and Construction of a Precision Prevention and Treatment System: Research on the Pathogenesis and Targeted Therapy of Limb Proliferative Diseases Caused by Somatic Activating Mutations. Date of approval: 11, November, 2022.
: The consent for publication was acquired from patients’ parents. All authors confirm their consent for publication.
: The authors declare that they have no competing interests.
